Your shopping cart is currently empty

NSC305787 hydrochloride ((Rac)-NSC305787 hydrochloride is a cell membrane permeable and selective and potent small molecule dual inhibitor of Cdc25 dual specificity phosphatase and EZR that displays antitumor activity in pancreatic cancer cells and inhibits Cdc25B2, Cdc25A, Cdc25B2 and Cdc25C.NSC 663284 inhibits NSD2 (IC50 of 170 nM) enzyme activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | - | In Stock | |
| 2 mg | $166 | 5 days | 5 days | |
| 5 mg | $277 | 5 days | 5 days |
| Description | NSC305787 hydrochloride ((Rac)-NSC305787 hydrochloride is a cell membrane permeable and selective and potent small molecule dual inhibitor of Cdc25 dual specificity phosphatase and EZR that displays antitumor activity in pancreatic cancer cells and inhibits Cdc25B2, Cdc25A, Cdc25B2 and Cdc25C.NSC 663284 inhibits NSD2 (IC50 of 170 nM) enzyme activity. |
| Targets&IC50 | Radixin:55 μM, PKCΙ:172.4 μM (Kd), MBP:58.9 μM, Ezrin:5.85 μM (Kd), Ezrin:8.3 μM, Moesin:9.4 μM |
| In vitro | NSC305787 hydrochloride, an inhibitor of ezrin, exhibits a Kd of 5.85 μM and demonstrates antitumor activity. With IC50 values of 8.3, 9.4, 55, and 58.9 μM, NSC305787 hydrochloride inhibits PKCΙ phosphorylation of Ezrin, Moesin, Radixin, and MBP, respectively. Binding to PKCΙ with a Kd value of 172.4 μM, NSC305787 hydrochloride primarily inhibits ezrin T567 phosphorylation through its binding to ezrin, not via the inhibition of PKCΙ kinase activity. In the context of K7M2 osteosarcoma (OS) cells, NSC305787 hydrochloride (1, 10 μM) displays inhibitory activity against ezrin-mediated invasion. Furthermore, at a concentration of 10 μM, NSC305787 hydrochloride diminishes cell motility phenotypes in zebrafish and hinders OS metastatic growth in lung organ culture[2]. |
| In vivo | In a mouse model,NSC305787 hydrochloride (i.p., 0.240 mg/kg/day) effectively suppresses ezrin-dependent osteosarcoma metastatic growth in the lung[1]. Additionally, in a transgenic mouse model of osteosarcoma (Osx-Cre+p53fl/flpRBfl/fl), NSC305787 hydrochloride (i.p., 240 μg/kg) exhibits a remarkable inhibition of pulmonary metastasis. Furthermore, it demonstrates a more favorable pharmacokinetic profile compared to NSC668394 in the same mouse model[1]. |
| Synonyms | (Rac)-NSC305787 hydrochloride |
| Molecular Weight | 481.89 |
| Formula | C25H31Cl3N2O |
| Cas No. | 53868-26-1 |
| Smiles | Cl.OC(C1CCCCN1)c1cc(nc2c(Cl)cc(Cl)cc12)C12CC3CC(CC(C3)C1)C2 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 5 mg/mL (10.38 mM), Sonication is recommended. H2O: <0.1 mg/mL (Insoluble) | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.08 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.